Established sites join Iterative Health’s elite site network, expanding the company’s cardiovascular research capabilities

CAMBRIDGE, Mass.: Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the acquisition of three cardiology sites from NextStage Clinical Research. Located across the key market of Texas, they bring experienced research teams, deep connections to community-based provider groups, and a proven track record in cardiovascular research – deepening Iterative Health’s reach into one of the highest-need therapeutic areas.

Cardiovascular disease affects nearly half of all U.S. adults, yet clinical trial access remains uneven across communities. Iterative Health’s site network model is built around embedding research within community care settings, giving patients access to innovative therapies and devices while providing biopharma and medical device sponsors with high-performing centers that reflect real-world populations. The acquisition is a direct extension of Iterative Health's cardiology strategy, adding proven sites in key markets where cardiovascular trials can meaningfully expand access to advanced care.

Spanning across Beaumont, Port Arthur, and Waco, Texas, the three sites are high-performing cardiovascular research centers with experienced teams, established operations, an active portfolio of cardiology trials, and engaged patient communities. This addition expands Iterative Health’s cardiology footprint and builds on the company’s capabilities across GI, hepatology, and obesity, reinforcing its position as a trusted partner across therapeutic areas.

“Joining Iterative Health is a natural next step for our site staff and the patients we serve,” said Donald S. Cross, MD, MHCDS, FACC, cardiologist and principal investigator at Waco Cardiology Associates. “Their network gives us the operational backbone and global reach to expand our impact, reach more patients across Texas, and contribute to cardiovascular research at a scale worthy of the patients who trust us with their care.”

Iterative Health brings the full depth of a mature research organization to every site in its network. The company’s 250-person team, including site staff and centralized operations across multiple therapeutic areas, supports clinical, regulatory, financial, and operational functions. Proprietary AI and engineering tools accelerate patient recruitment, improve efficiency, and advance trial design. With more than 100 sites on three continents, the company has built a track record of industry-leading trial speed and enrollment performance, advancing cardiovascular care in communities where engaged physicians, established patient relationships, and centralized support are already in place.

“These established sites are a key addition as we build out our cardiology focus within Iterative Health's global network,” said Jonathan Ng, founder and CEO of Iterative Health. “They bring experienced teams with deep community trust and a shared understanding that embedding research in those settings is how you advance both access and outcomes. That shared belief is what makes this the right fit, and we look forward to the impact these sites will contribute as part of our growing cardiology network.”

About Iterative Health

Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates.

Fonte: Business Wire